NASDAQ:JAGX - Jaguar Health Stock Price, Forecast & News

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Jaguar Health Inc (NASDAQ:JAGX) released its quarterly earnings results on Thursday, November, 14th. The biotechnology company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($0.25) by $1.69. The biotechnology company earned $0.97 million during the quarter, compared to analysts' expectations of $4.22 million. Jaguar Health had a negative net margin of 771.25% and a negative return on equity of 675.03%. View Jaguar Health's Earnings History.

Jaguar Health is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Jaguar Health.

2 analysts have issued twelve-month price objectives for Jaguar Health's shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate Jaguar Health's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 354.1% from the stock's current price. View Analyst Price Targets for Jaguar Health.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.

News stories about JAGX stock have trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jaguar Health earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Jaguar Health.

Some companies that are related to Jaguar Health include Arcturus Therapeutics (ARCT), Harrow Health (HROW), Mustang Bio (MBIO), Aldeyra Therapeutics (ALDX), Obseva (OBSV), Galectin Therapeutics (GALT), Akorn (AKRX), Spero Therapeutics (SPRO), TAIWAN LIPOSOME/S (TLC), PhaseBio Pharmaceuticals (PHAS), Corvus Pharmaceuticals (CRVS), Agile Therapeutics (AGRX), Xeris Pharmaceuticals (XERS), CannTrust (CTST) and Adamas Pharmaceuticals (ADMS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Conatus Pharmaceuticals (CNAT), Biopharmx (BPMX), Cara Therapeutics (CARA), Neovasc (NVCN), Precipio (PRPO), PTC Therapeutics (PTCT), Biocept (BIOC), Cascadian Therapeutics (CASC), Cellectar Biosciences (CLRB) and FuelCell Energy (FCEL).

(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JAGX stock can currently be purchased for approximately $0.88.

Jaguar Health has a market capitalization of $45.05 million and generates $4.42 million in revenue each year. The biotechnology company earns $-32,150,000.00 in net income (profit) each year or ($158.74) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.View Additional Information About Jaguar Health.

The official website for Jaguar Health is http://www.jaguaranimalhealth.com/.

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.